Ian A. Cook

Chief Tech/Sci/R&D Officer at NeuroSigma, Inc.

64 year

Consumer Services

Health Technology

Profile

Ian A.
Cook is currently the Director of the Transcranial Magnetic Stimulation Service at the Semel Institute for Neuroscience & Human Behavior, Chief Medical Officer & Senior Vice President at NeuroSigma, Inc., Professor at the David Geffen School of Medicine, and Professor at the Henry Samueli School of Engineering & Applied Science.
He received his undergraduate degree from Princeton University and his doctorate from Yale School of Medicine.

Ian A. Cook active positions

Companies	Position	Start
NeuroSigma, Inc. NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA.	Chief Tech/Sci/R&D Officer	2013-12-31
Henry Samueli School of Engineering & Applied Science	Corporate Officer/Principal	2013-06-30
David Geffen School of Medicine	Corporate Officer/Principal	2010-06-30
Semel Institute For Neuroscience & Human Behavior	Corporate Officer/Principal	2006-12-31

All active positions of Ian A. Cook

Training of Ian A. Cook

Princeton University	Undergraduate Degree
Yale School of Medicine	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Ian A. Cook's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
NeuroSigma, Inc. NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA.	Health Technology